Review
Aug 2026
FAK and PYK2 as Central Resistance Nodes in Non-Small Cell Lung Cancer: Signalling Crosstalk and Combination Therapeutic Strategies
Although FAK/PYK2-targeted monotherapy has demonstrated limited clinical efficacy, rational combination strategies involving EGFR tyrosine kinase inhibitors, MAPK inhibitors, chemotherapy, or immunotherapy have shown promising synergistic effects.
Shatrudhan Prajapati, Shabana Khatoon, A. Singh et al.
· Current Enzyme Inhibition · 0 citations